© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Scientific Commentary |
Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP–parkinsonism, by D. Williams, R. de Silva, D. Paviour, et al. (Brain-2004-01045.R1)
| The first 10% of the full text of this article appears below. |
When J. Clifford Richardson presented the first clinical report of eight cases of progressive supranuclear palsy (PSP) at the American Neurological Association meeting in June 1963, a number of eminent discussants felt that the condition must be rare, and wondered whether a toxic aetiology might be responsible, as the cases were clustered in Ontario, Canada. With impressive foresight, Richardson remarked: ‘I doubt very much that there is any local geographic incidence. I expect that a good many cases of the same disease will be identified in other areas’ (Steele, 1992
).
Fast-forward 40 years, and the prevalence of PSP has been established by two community-based UK studies to be at least 5 per 100 000 (Schrag et al
Regional Neurosciences Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK
E-mail: d.j.burn@ncl.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. I. Golbe, B. F. Boeve, B. M. Keegan, and J. E. Parisi An 81-year-old man with imbalance and memory impairment Neurology, April 3, 2007; 68(14): 1147 - 1152. [Full Text] [PDF]
|
|